Glytec has raised $36m in growth investment, led by Savitr Capital and Hayfin Capital Management, to enhance its AI-powered diabetes technology platform.
The funding will support the expansion of Glytec’s Glucommander SaaS solution.
Also, it will help the company advance the development of its new technologies to combat the global diabetes health crisis and related co-morbidities.
Savitr Capital managing member Andrew Midler said: “Glytec stands at the intersection of cutting-edge AI and critical healthcare need.
“Their proven track record with Glucommander and their broader vision for combining digital technology and AI to help hospitals improve patient care make Glytec a compelling investment.”
Hayfin Capital Management managing director Andrew Merrill said: “We are impressed by Glytec’s robust technology, clinical efficacy, and commitment to improving patient lives.
“Their platform approach to metabolic health, particularly their success in inpatient glucose management, demonstrates a profound understanding of complex clinical challenges and a scalable solution to address them.”
Glytec’s platform enables healthcare providers to deliver precision insulin management, optimising metabolic health outcomes.
Its Glucommander product is a cloud-based solution intended for inpatient glycaemic management, utilised by over 400 hospitals in the US.
The product is designed to improve patient safety, reduce costs, and increase revenue by shortening hospital stays.
With upcoming CMS quality measures for glycaemic management, Glytec’s solutions are crucial for healthcare organisations to enhance patient care and meet regulatory standards.
The investment will also support a rapid response to these measures, ensuring hospitals can maintain accountability for inpatient glycaemic control.
Glytec CEO Patrick Cua said: “This investment is a pivotal moment for Glytec, validating our vision of a future where deep data-driven insights empower clinicians to deliver highly individualised and proactive care for diabetes and metabolic conditions.
“Savitr Capital and Hayfin Capital share our belief in the transformative power of technology to improve patient outcomes and alleviate the burden of complex chronic diseases.
“This capital will enable us to expand our R&D initiatives, scale our platform, and continue to attract top-tier talent as we revolutionise metabolic healthcare.”
Earlier this year, Glytec entered a strategic partnership with TidalHealth, an integrated health system based in Salisbury, Maryland, to advance diabetes and glycemic management.
